Botulinum Toxin Type A
Research News and Information

Sunday, November 22, 2009

Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury.

30 Oct 2009 BACKGROUND: Pressure sores are a significant secondary complication in spinal cord injured patients. A new indication for botulinum toxin type A is described here, in treatment of recurrent muscular spasms that had hampered the healing of a chronic ... Read more...

Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia.

30 Oct 2009 OBJECTIVE: The aim of this pilot study was to examine changes in different aspects of impairment, including spasticity in the upper limbs, of hemiplegic children following botulinum toxin type A intervention. Progress was assessed using standard ... Read more...

The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections.

29 Sep 2009 BACKGROUND: Palmar hyperhidrosis is an uncomfortable condition that can severely affect a patient's quality of life. Injections of botulinum toxin have proven to be an efficient treatment modality, however the pain associated with palmar injections ... Read more...

Latest indexed articles for 'Botulinum Toxin Type A'

These are the very latest articles for this heading:

• Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury. 30 Oct 2009
• Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia. 30 Oct 2009
• The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. 29 Sep 2009
• A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. 29 Sep 2009
• Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. 29 Sep 2009
• Effectiveness of sedation using nitrous oxide compared with enteral midazolam for botulinum toxin A injections in children. 29 Sep 2009
• [Therapeutic modalities in the treatment of palmar and axillary hyperhidrosis] 18 Sep 2009
• The use of botulinum type A toxin in the treatment of idiopathic clubfoot: 5-year follow-up. 30 Aug 2009
• The effectiveness of botulinum A toxin as an adjunct to the treatment of clubfeet by the Ponseti method: a randomized, double blind, placebo controlled study. 30 Aug 2009
• Treatment of severe achalasia during pregnancy with esophagoscopic injection of botulinum toxin A: a case report. 30 Aug 2009
• Medical treatment for pregnant women: balancing risks and benefits. 30 Aug 2009
• Letter to the editor on 'Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials'. 30 Aug 2009
• I have an anal fissure that isn't getting better even though I've increased my fiber and water intake over past few months. My doctor is recommending surgery to cut part of the anal sphincter. Are there any other treatment options? 30 Aug 2009
• Differences in botulinum toxins: time to end the confusion. 30 Aug 2009
• Botulinum toxin in aesthetic applications: 'how often misused words generate misleading thoughts'. (Response to: De Boulle K. Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. J Cosmet Laser Ther. 2008;10:87-92). 30 Aug 2009
• Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225). 30 Aug 2009
• I have read that Botox now comes with a warning. How safe is it for removing wrinkles? 30 Aug 2009
• Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapy. 30 Aug 2009
• A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke. 30 Aug 2009
• Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Botulinum Toxin Type A'

Definition: A 150 kDa neurotoxic protein produced by CLOSTRIDIUM BOTULINUM. When consumed in contaminated food it can cause paralysis and death. In its purified form, it has been used in the treatment of BLEPHAROSPASM and STRABISMUS.

Registry Number: 0

Descriptor UI: D019274

Alternative terms: Botulinum Toxin Type A; Botulinum Neurotoxin A; Neurotoxin A, Botulinum; Clostridium Botulinum Toxin Type A; Botulinum A Toxin; Toxin, Botulinum A; Clostridium botulinum A Toxin; Dysport; Lasa Brand of Botulinum A Toxin; Speywood Brand of Botulinum A Toxin; Ispen Brand of Botulinum A Toxin; Oculinum; Botox; Merz Brand of Botulinum A Toxin; Allergan Brand of Botulinum A Toxin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Neuromuscular Agents; Neurotoxins;

Tree Number: D12.776.097.156.050; D23.946.123.179.050;

History Note: 97

Technical Notes: /antag permitted but consider also BOTULINUM ANTITOXIN